AlzeCure Pharma

The Rights Issue was approved at the Extraordinary General Meeting of AlzeCure on April 25, 2024 and the subscription period expired on May 17, 2024. Formue Nord, which co-guaranteed the Rights Issue, has the right to choose between cash compensation for its commitment or compensation in the form of newly issued shares. To the extent that compensation in the form of shares is chosen, the compensation amounts to twelve percent of the warranted amount, corresponding to SEK 1 641 736, which shall be set off against a subscription price corresponding to the subscription price in the Rights Issue, i.e. SEK 1,70 per share.

Formue Nord has chosen compensation in the form of shares, which is why AlzeCure's Board of Directors today, in accordance with what the warranty agreement stipulates, has decided on a directed new issue to Formue Nord of a maximum of 965 727 shares at a subscription price of SEK 1,70, where the price for newly subscribed shares is set off against the requirement for payment of compensation.

"We are happy and grateful that Formue Nord chooses to receive shares in the company instead of us paying them for their commitment. This improves our liquidity and also shows that they believe in AlzeCure. With the improved liquidity, we can now invest in further activities that benefit the company", says Martin Jönsson, CEO AlzeCure.

Number of shares and share capital
Following registration of the Rights Issue with the Swedish Companies Registration Office, the Company's share capital will increase by SEK 24 143,175 to a total of SEK 2 152 380. The number of shares in the Company will increase by 965 727 shares to a total of 86 095 200 shares.